Understanding The Potential of CYP2A6 as A Drug Target (G1548)

Target Name: CYP2A6

NCBI ID: G1548

CYP2A6

Understanding The Potential of CYP2A6 as A Drug Target

CYP2A6 (Flavoprotein-linked monoxygenase), also known as CYP2A6 gene, is a gene that encodes a protein known as CYP2A6. This protein is a key enzyme in the metabolism of many drugs, including many statins, antidepressants, and opioids. Because of its Being highly conserved, CYP2A6 becomes a very attractive drug target. Currently, several drugs targeting CYP2A6 have been approved, and these drugs are mainly used to treat diseases such as hypercholesterolemia, hypertriglyceridemia, and hypertension. However, CYP2A6 still has great potential in drug discovery and development and is expected to become a target for more drugs in the future.

CYP2A6 is a membrane protein located on the inside of the cell membrane. Its function is to synthesize a series of biologically active compounds within cells, including precursors of some drugs. CYP2A6 is a heterodimer composed of 5 subunits, each of which is composed of 2 conserved helices. It plays important physiological roles within cells, especially in drug metabolism.

CYP2A6 genotypes and alleles are well conserved in humans and other organisms. This makes CYP2A6 a good drug target because cells express and function very similarly even with different genotypes. Furthermore, due to the highly conserved nature of the CYP2A6 protein, scientists have been able to predict its three-dimensional structure. This provides great convenience for drug design, because scientists can design new drugs based on these structures.

CYP2A6 is a very important target in the drug discovery process. Because the metabolism of many drugs involves CYP2A6, studying the function of CYP2A6 is very important for understanding the mechanism of action and pharmacology of drugs. In addition, studying the function of CYP2A6 is also attractive for the development of new drug targets. Through drug intervention targeting CYP2A6, scientists can study how drugs affect the function of CYP2A6 and explore new drug targets.

In addition to its role in drug discovery, CYP2A6 is also considered a good biomarker. Because the function of CYP2A6 in drug metabolism has been demonstrated, drug metabolism rates can be assessed by measuring CYP2A6 levels. In addition, CYP2A6 levels can also be used as an indicator of treatment effectiveness, because the decrease in CYP2A6 levels after drug treatment can reflect the therapeutic effect of the drug.

CYP2A6 is an attractive drug target because it plays an important role in drug metabolism and is highly conserved. Currently, several drugs targeting CYP2A6 have been approved, but the efficacy and safety of these drugs still need to be improved. Therefore, CYP2A6 is expected to become the target of more drugs in the future, bringing more hope for drug discovery and treatment.

Protein Name: Cytochrome P450 Family 2 Subfamily A Member 6

Functions: Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity

The "CYP2A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets